[¹⁸F]-(S)-N,N-diethyl-9-(2-fluoroethyl)-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-carboxamide | 1274863-98-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: [¹⁸F]-(S)-N,N-diethyl-9-(2-fluoroethyl)-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-carboxamide
• 英文别名: [¹⁸F]GE-180；Flutriciclamide (18F)；(4S)-N,N-diethyl-9-(2-(18F)fluoranylethyl)-5-methoxy-1,2,3,4-tetrahydrocarbazole-4-carboxamide
• CAS: 1274863-98-7
• 化学式: C₂₀H₂₇FN₂O₂
• 分子量: 345.447
• InChiKey: ZVDVQPLDTTXLKI-LSKWOKDISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  34.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  9-(2-benzyloxyethyl)-8-chloro-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-carboxylic acid 在 草酰氯 、 氢氟酸 、 palladium 10% on activated carbon 、 氢气 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 异丙醇 、 乙腈 为溶剂， 反应 56.35h， 生成 [¹⁸F]-(S)-N,N-diethyl-9-(2-fluoroethyl)-5-methoxy-2,3,4,9-tetrahydro-1H-carbazole-4-carboxamide
  参考文献：
  名称：

  In vivo imaging method of mood disorders

  摘要：

  本发明提供了一种在诊断和/或监测情绪障碍方面有用的方法，其中存在PBR异常表达。该发明的方法对于区分所述情绪障碍和其他情况有用，其他情况中PBR表达正常但症状可能类似于所述情绪障碍。

  公开号：

  US09168317B2

文献信息

• In vivo imaging method for cancer
  申请人：Jones Paul Alexander

  公开号：US09314541B2

  公开（公告）日：2016-04-19

  The present invention provides a method useful in the diagnosis and monitoring of cancer wherein there is an abnormal expression of PBR. The method of the invention is particularly useful in evaluating the severity of the cancer, e.g. PBR expression correlates with cell proliferation rates, metastatic potential, tumor aggressiveness, malignancy progression. The method of the invention can therefore be applied in the determination of likely disease progression and in making an associated prognosis. Furthermore, the method of the invention can find use in determining the likely success of certain therapeutic approaches, or in the evaluation of the efficacy of certain proposed new treatments.

  本发明提供了一种在癌症的诊断和监测中有用的方法，其中PBR的表达异常。本发明的方法特别适用于评估癌症的严重程度，例如PBR表达与细胞增殖率、转移潜力、肿瘤侵袭性、恶性进展相关。因此，本发明的方法可以应用于确定可能的疾病进展，并作出相关的预后。此外，本发明的方法可以用于确定某些治疗方法的成功可能性，或评估某些提议的新治疗方法的有效性。
• IN VIVO IMAGING METHOD OF MOOD DISORDERS
  申请人：Jones Paul Alexander

  公开号：US20130177501A1

  公开（公告）日：2013-07-11

  The present invention provides a method useful in the diagnosis and/or monitoring of mood disorders wherein there is an abnormal expression of PBR. The method of the invention is useful in the differential diagnosis of said mood disorders and other conditions where there is no abnormal expression of PBR but where the symptoms may be similar to those of said mood disorder.

  本发明提供了一种在诊断和/或监测情绪障碍方面有用的方法，其中存在PBR异常表达。本发明的方法对于区分所述情绪障碍和其他情况有用，其他情况中PBR表达正常但症状可能类似于所述情绪障碍的情况。
• The development of an automated and GMP compliant FASTlab™ Synthesis of [¹⁸F]GE-180; a radiotracer for imaging translocator protein (TSPO)
  作者：Torild Wickstrøm、Alan Clarke、Ingvil Gausemel、Eric Horn、Karina Jørgensen、Imtiaz Khan、Dimitrios Mantzilas、Thanushan Rajanayagam、Dirk-Jan In 't Veld、William Trigg

  DOI：10.1002/jlcr.3112

  日期：2014.1

  The level of the translocator protein (TSPO) increases dramatically in microglial cells when the cells are activated in response to neuronal injury and insult. The radiotracer [18F]GE-180 binds selectively and with high affinity to TSPO and can therefore be used to measure neuroinflammation in a variety of disease states. An optimized, automated synthesis of [18F]GE-180 has been developed for the GE FASTlab™ synthesizer. The entire process takes place on the single-use cassette. The radiolabelling is performed by nucleophilic fluorination of the S- enantiomer mesylate precursor. The crude product is purified post-radiolabelling using two solid-phase extraction cartridges integrated on the cassette. Experimental design and multivariate data analysis were used to assess the robustness, and critical steps were optimized with respect to efficacy and quality. The average radiochemical yield is 48% (RSD 6%, non-decay corrected), and the synthesis time including purification is approximately 43 min. The radiochemical purity is ≥95% for radioactive concentration ≤1100 MBq/mL. The total amount of precursor-related chemical impurities is 1–2 µg/mL. The use of solid-phase extraction purification results in a robust GMP compliant process with a product of high chemical and radiochemical purity and consistent performance across positron emission tomography (PET) centers.

  当小胶质细胞因神经元损伤和侮辱而被激活时，小胶质细胞中转运蛋白（TSPO）的水平会急剧升高。放射性示踪剂[18F]GE-180可选择性地与TSPO高亲和力结合，因此可用于测量各种疾病状态下的神经炎症。 我们为 GE FASTlab™ 合成器开发了一种优化的[18F]GE-180 自动合成方法。整个过程在一次性使用盒上进行。通过对 S-对映体甲磺酸盐前体进行亲核氟化来进行放射性标记。放射性标记后的粗产品使用集成在盒上的两个固相萃取柱进行纯化。实验设计和多元数据分析用于评估稳健性，并对关键步骤的功效和质量进行了优化。 平均放射化学收率为 48%（RSD 为 6%，无衰变校正），包括纯化在内的合成时间约为 43 分钟。放射性浓度≤1100 MBq/mL时，放射化学纯度≥95%。前体相关化学杂质的总量为 1-2 µg/mL。 采用固相萃取纯化技术可实现符合 GMP 标准的稳健工艺，产品具有很高的化学和放射化学纯度，在各正电子发射断层扫描（PET）中心具有一致的性能。
• ACTIVE ENANTIOMER
  申请人：ACHANATH RADHA

  公开号：US20110070161A1

  公开（公告）日：2011-03-24

  The present invention provides a PET tracer that has improved properties for imaging the peripheral benzodiazepine receptor (PBR) as compared with known such PET tracers. The present invention also provides a precursor compound useful in the preparation of the PET tracer of the invention and methods for the preparation of said precursor compound and said PET tracer. Also provided by the present invention is a radiopharmaceutical composition comprising the PET tracer of the invention. Methods for using the PET tracer and the radiopharmaceutical composition are also provided.

  本发明提供了一种PET示踪剂，与已知的PET示踪剂相比，具有改进的性能，可用于成像外周苯二氮卓类受体（PBR）。本发明还提供了一种在制备该发明的PET示踪剂中有用的前体化合物，以及制备所述前体化合物和所述PET示踪剂的方法。本发明还提供了一种包括该发明的PET示踪剂的放射性药物组合物。本发明还提供了使用该PET示踪剂和放射性药物组合物的方法。
• IN VIVO IMAGING METHOD FOR CANCER
  申请人：Jones Paul Alexander

  公开号：US20130183240A1

  公开（公告）日：2013-07-18

  The present invention provides a method useful in the diagnosis and monitoring of cancer wherein there is an abnormal expression of PBR. The method of the invention is particularly useful in evaluating the severity of the cancer, e.g. PBR expression correlates with cell proliferation rates, metastatic potential, tumour aggressiveness, malignancy progression. The method of the invention can therefore be applied in the determination of likely disease progression and in making an associated prognosis. Furthermore, the method of the invention can find use in determining the likely success of certain therapeutic approaches, or in the evaluation of the efficacy of certain proposed new treatments.

  本发明提供了一种在癌症诊断和监测中有用的方法，其中PBR的表达异常。本发明的方法特别适用于评估癌症的严重程度，例如PBR的表达与细胞增殖率、转移潜力、肿瘤侵袭性、恶性进展相关。因此，本发明的方法可用于确定可能的疾病进展，并作出相关预后。此外，本发明的方法可用于确定某些治疗方法的可能成功率，或评估某些拟议新治疗方法的疗效。